Mar 4, 2026 04:01PM
Jan 9, 2026 07:02AM
Jan 9, 2026 07:00AM
Nov 5, 2025 04:01PM
Oct 8, 2025 07:00AM
Oct 8, 2025 07:00AM
Sep 4, 2025 07:00AM Aquestive says FDA won't require advisory meeting for Anaphylm drug
Sep 4, 2025 07:00AM
Aug 11, 2025 04:01PM
Jul 15, 2025 07:00AM
Jul 15, 2025 07:00AM
Jun 17, 2025 06:39AM
Jun 16, 2025 07:02AM
Jun 16, 2025 07:00AM Aquestive Therapeutics Announces FDA Acceptance of New Drug Application and PDUFA Date for Anaphylm™ for the Treatment of Severe Allergic Reactions
May 13, 2025 03:26PM
May 12, 2025 04:01PM
Apr 12, 2024 04:01PM
Mar 5, 2024 05:05PM
Nov 6, 2023 04:37PM
Nov 6, 2023 04:37PM
Oct 9, 2023 08:00AM Aquestive Therapeutics Inc. (AQST) Provides Business Update
Oct 9, 2023 08:00AM
Sep 11, 2023 08:02AM
Sep 11, 2023 08:00AM
Sep 6, 2022 04:04PM
Aug 2, 2022 04:02PM
Aug 2, 2022 04:02PM
May 17, 2022 04:01PM Aquestive Therapeutics Inc. (AQST) Announces CEO Transition
May 17, 2022 04:01PM
May 17, 2022 04:01PM
May 3, 2022 05:41PM
May 3, 2022 05:40PM
May 3, 2022 05:40PM
Mar 10, 2022 06:38AM
Mar 8, 2022 04:57PM Aquestive Therapeutics Inc. (AQST) Reports Full Year 2021 Results
Mar 8, 2022 04:56PM
Mar 8, 2022 04:56PM
Dec 21, 2021 05:15AM
Dec 20, 2021 10:49PM
Dec 20, 2021 10:49PM
Dec 13, 2021 08:00AM
Dec 13, 2021 08:00AM Aquestive Therapeutics Receives Written Response to Pre-IND Submission for AQST-109 (epinephrine prodrug sublingual film) and Begins Recruitment for its Epinephrine Film Pharmacokinetic and Safety Tri
Nov 2, 2021 04:30PM
Nov 2, 2021 04:30PM
Oct 7, 2021 05:33AM
Oct 6, 2021 05:59PM
Oct 6, 2021 05:59PM
Aug 9, 2021 08:00AM
Aug 9, 2021 08:00AM Aquestive Therapeutics Negotiates Six Month Extension to June 30, 2022 for Additional Libervant™ Related Capital Under Current Debt Agreement
Aug 6, 2021 08:00AM

14,982 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All